SCHEMBL6507229

SCHEMBL6507229

NC(=O)C(F)CF

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28033794 0.75
SCHEMBL22081743 0.75
SCHEMBL1031070 0.73
SCHEMBL27685993 0.73
SCHEMBL6349189 0.73
SCHEMBL27705009 0.73
SCHEMBL6007710 0.73
SCHEMBL14012404 0.71
SCHEMBL1708125 0.71
SCHEMBL1031676 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025262036-A1 METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION RNASSIST LTD (GB) 2025-12-26 WO disclosed
CN-118369317-A Melanocortin 4 receptor antagonists and uses thereof 辉瑞大药厂 2024-07-19 CN disclosed
EP-4373577-A1 ACTRII PROTEINS AND USES THEREOF Acceleron Pharma Inc. (US) 2024-05-29 EP disclosed
WO-2024054985-A2 METHODS OF ADMINISTERING AN ACTIVIN TYPE IIB VARIANT KEROS THERAPEUTICS, INC. (US) 2024-03-14 WO disclosed
EP-3827241-B1 DISSOCIATION OF BIOLOGICAL SAMPLES GOLDSBOROUGH ANDREW SIMON (FR) 2024-03-13 EP disclosed
US-20240027309-A1 SIMPLE FIXATION AND STABILISATION RNASSIST LTD (GB) 2024-01-25 US disclosed
EP-4274600-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION Acceleron Pharma Inc. (US) 2023-11-15 EP disclosed
US-20230220313-A1 COMPOSITION AND METHOD FOR INACTIVATING A VIRUS RNASSIST LTD. (GB) 2023-07-13 US disclosed
EP-4168037-A1 ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) Acceleron Pharma Inc. (US) 2023-04-26 EP disclosed
EP-4142769-A1 ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION Acceleron Pharma Inc. (US) 2023-03-08 EP disclosed
US-20140295404-A1 SAMPLE FIXATION AND STABILISATION RNASSIST LTD. (GB) 2014-10-02 US disclosed
WO-2014131906-A1 SAMPLE FIXATION AND STABILISATION GOLDSBOROUGH ANDREW SIMON (FR) 2014-09-04 WO disclosed
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed
US-6710060-B2 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2004-03-23 US disclosed
EP-1268474-A2 SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2003-01-02 EP disclosed
US-20020188006-A1 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-12-12 US disclosed
EP-1182192-A1 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-02-27 EP disclosed
WO-2001074811-A2 SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-11 WO disclosed
EP-0383128-B1 PROCESS FOR THE FLUORINATION OF ACRYLIC ACID AND DERIVATIVES THEREOF, AND FLUORINATED ESTERS OF 2,3-DIFLUOROPROPIONIC ACID BAYER AG (DE) 1993-03-31 EP disclosed
US-5072030-A PROCESS FOR THE FLUORINATION OF ACRYLIC ACID AND DERIVATIVES THEREOF AND NOVEL FLUORINATED ESTERS OF 2,3-DIFLUOROPROPIONIC ACID BAYER AKTIENGESELLSCHAFT (DE) 1991-12-10 US disclosed